Intractable and highly active relapsing multiple sclerosis – role of alemtuzumab
Divyanshu Dubey,1 Christopher A Cano,1 Olaf Stuve1–3 1Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, 2Neurology Section, VA North Texas Health Care System, Medical Service, Dallas, TX, USA; 3Department of Neurology, Klinikum rechts der Isar...
Guardado en:
Autores principales: | Dubey D, Cano CA, Stuve O |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e848b4d154864ff8a42f4460ff32a5db |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis
por: Babij R, et al.
Publicado: (2015) -
Disease-modifying therapies in relapsing–remitting multiple sclerosis
por: Fabricio González-Andrade, et al.
Publicado: (2010) -
Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis
por: Lugaresi A, et al.
Publicado: (2013) -
Can a physician predict the clinical response to first-line immunomodulatory treatment in relapsing–remitting multiple sclerosis?
por: Mezei Z, et al.
Publicado: (2012) -
Disconnection of the hippocampus and amygdala associated with lesion load in relapsing–remitting multiple sclerosis: a structural and functional connectivity study
por: Zhou F, et al.
Publicado: (2015)